Risk increased with intravenous vitamin C versus placebo for adults with sepsis in the ICU receiving vasopressor therapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 17, 2022 (HealthDay News) — For adults with sepsis who are receiving vasopressor therapy in the intensive care unit (ICU), intravenous vitamin C is associated with an increased risk for a composite of death or persistent organ dysfunction at 28 days, according to a study published online June 15 in the New England Journal of Medicine<\/em> to coincide with the annual Critical Care Reviews Meeting, held from June 15 to 17 in Belfast.<\/em><\/p>\n Fran \u00a7ois Lamontagne, M.D., from the Universit \u00a9 de Sherbrooke in Canada, and colleagues conducted a trial in which 872 adults with sepsis who were receiving vasopressor therapy in the ICU were randomly assigned to an infusion of either vitamin C (435 patients) or matched placebo (437 patients).<\/p>\n The researchers found that the primary outcome (composite of death or persistent organ dysfunction on day 28) occurred in 44.5 and 38.5 percent of patients in the vitamin C and placebo groups, respectively (risk ratio, 1.21; 95 percent confidence interval, 1.04 to 1.40; P = 0.001). Death occurred in 35.4 and 31.6 percent of patients in the vitamin C and placebo groups, respectively, at day 28 (risk ratio, 1.17; 95 percent confidence interval, 0.98 to 1.40), and persistent organ dysfunction occurred in 9.1 and 6.9 percent, respectively (risk ratio, 1.30; 95 percent confidence interval, 0.83 to 2.05). <\/p>\n “This was an unexpected finding, and the secondary analyses — which included the evaluation of five biomarkers of tissue dysoxia, inflammation, and endothelial injury measured up to day seven — did not determine a putative mechanism for harm,” the authors write.<\/p>\n Nova Biomedical Canada provided glucometers, testing strips, and control solutions.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n